Immunocore Holdings plc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Immunocore Holdings plc (IMCR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- Immunocore Holdings plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $12.00K.
- Immunocore Holdings plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.21M, a 81.30% decline from fiscal 2024.
- Immunocore Holdings plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $6.48M, a 132.91% increase from fiscal 2023.
- Immunocore Holdings plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.78M, a 7.88% decline from fiscal 2022.
- Immunocore Holdings plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.02M, a 6765.91% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2025-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.21M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $6.48M 10-K · filed 2026-02-25 | ||
| 2023-12-31 | $2.78M 10-K · filed 2026-02-25 | ||
| 2022-12-31 | $3.02M 10-K · filed 2025-02-26 | ||
| 2021-12-31 | $44.00K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |